nodes	percent_of_prediction	percent_of_DWPC	metapath
Mycophenolate mofetil—UGT2B7—Epirubicin—testicular cancer	0.0717	0.102	CbGbCtD
Mycophenolate mofetil—UGT1A1—Etoposide—testicular cancer	0.0483	0.0686	CbGbCtD
Mycophenolate mofetil—ABCG2—Dactinomycin—testicular cancer	0.0471	0.0669	CbGbCtD
Mycophenolate mofetil—SLCO1B3—Methotrexate—testicular cancer	0.038	0.0539	CbGbCtD
Mycophenolate mofetil—ABCC2—Carboplatin—testicular cancer	0.035	0.0497	CbGbCtD
Mycophenolate mofetil—ABCC2—Vinblastine—testicular cancer	0.0326	0.0463	CbGbCtD
Mycophenolate mofetil—ABCG2—Carboplatin—testicular cancer	0.0317	0.045	CbGbCtD
Mycophenolate mofetil—CYP3A5—Ifosfamide—testicular cancer	0.0308	0.0438	CbGbCtD
Mycophenolate mofetil—ABCC2—Cisplatin—testicular cancer	0.0299	0.0425	CbGbCtD
Mycophenolate mofetil—CYP2C8—Ifosfamide—testicular cancer	0.0296	0.0421	CbGbCtD
Mycophenolate mofetil—ABCC2—Etoposide—testicular cancer	0.0294	0.0417	CbGbCtD
Mycophenolate mofetil—ABCG2—Cisplatin—testicular cancer	0.027	0.0384	CbGbCtD
Mycophenolate mofetil—ABCG2—Etoposide—testicular cancer	0.0266	0.0377	CbGbCtD
Mycophenolate mofetil—SLCO1B1—Methotrexate—testicular cancer	0.0221	0.0314	CbGbCtD
Mycophenolate mofetil—ABCC2—Doxorubicin—testicular cancer	0.02	0.0285	CbGbCtD
Mycophenolate mofetil—ABCC2—Methotrexate—testicular cancer	0.0194	0.0276	CbGbCtD
Mycophenolate mofetil—ABCG2—Doxorubicin—testicular cancer	0.0181	0.0257	CbGbCtD
Mycophenolate mofetil—ABCG2—Methotrexate—testicular cancer	0.0176	0.0249	CbGbCtD
Mycophenolate mofetil—ABCB1—Dactinomycin—testicular cancer	0.017	0.0241	CbGbCtD
Mycophenolate mofetil—CYP3A5—Etoposide—testicular cancer	0.0147	0.0209	CbGbCtD
Mycophenolate mofetil—CYP2C8—Etoposide—testicular cancer	0.0142	0.0201	CbGbCtD
Mycophenolate mofetil—ALB—Methotrexate—testicular cancer	0.0121	0.0172	CbGbCtD
Mycophenolate mofetil—CYP3A4—Ifosfamide—testicular cancer	0.012	0.0171	CbGbCtD
Mycophenolate mofetil—ABCB1—Vinblastine—testicular cancer	0.0106	0.0151	CbGbCtD
Mycophenolate mofetil—ABCB1—Cisplatin—testicular cancer	0.00975	0.0139	CbGbCtD
Mycophenolate mofetil—ABCB1—Etoposide—testicular cancer	0.00958	0.0136	CbGbCtD
Mycophenolate mofetil—ABCB1—Doxorubicin—testicular cancer	0.00654	0.00928	CbGbCtD
Mycophenolate mofetil—CYP3A4—Vinblastine—testicular cancer	0.00637	0.00905	CbGbCtD
Mycophenolate mofetil—ABCB1—Methotrexate—testicular cancer	0.00633	0.00899	CbGbCtD
Mycophenolate mofetil—CYP3A4—Etoposide—testicular cancer	0.00574	0.00815	CbGbCtD
Mycophenolate mofetil—CYP3A4—Doxorubicin—testicular cancer	0.00392	0.00556	CbGbCtD
Mycophenolate mofetil—UGT1A6—testis—testicular cancer	0.00224	0.0766	CbGeAlD
Mycophenolate mofetil—IMPDH2—seminal vesicle—testicular cancer	0.00206	0.0705	CbGeAlD
Mycophenolate mofetil—IMPDH1—seminal vesicle—testicular cancer	0.00204	0.07	CbGeAlD
Mycophenolate mofetil—CES2—seminal vesicle—testicular cancer	0.00187	0.0641	CbGeAlD
Mycophenolate mofetil—IMPDH2—gonad—testicular cancer	0.00149	0.0509	CbGeAlD
Mycophenolate mofetil—CES2—gonad—testicular cancer	0.00135	0.0463	CbGeAlD
Mycophenolate mofetil—IMPDH2—female gonad—testicular cancer	0.00121	0.0414	CbGeAlD
Mycophenolate mofetil—IMPDH1—female gonad—testicular cancer	0.0012	0.0411	CbGeAlD
Mycophenolate mofetil—CES2—female gonad—testicular cancer	0.0011	0.0376	CbGeAlD
Mycophenolate mofetil—IMPDH2—testis—testicular cancer	0.00107	0.0367	CbGeAlD
Mycophenolate mofetil—IMPDH1—testis—testicular cancer	0.00107	0.0365	CbGeAlD
Mycophenolate mofetil—CES2—testis—testicular cancer	0.000974	0.0334	CbGeAlD
Mycophenolate mofetil—UGT2B7—testis—testicular cancer	0.000974	0.0334	CbGeAlD
Mycophenolate mofetil—CES1—female gonad—testicular cancer	0.000904	0.031	CbGeAlD
Mycophenolate mofetil—CES1—testis—testicular cancer	0.000802	0.0275	CbGeAlD
Mycophenolate mofetil—IMPDH2—lymph node—testicular cancer	0.000777	0.0266	CbGeAlD
Mycophenolate mofetil—IMPDH1—lymph node—testicular cancer	0.000772	0.0264	CbGeAlD
Mycophenolate mofetil—ABCG2—seminal vesicle—testicular cancer	0.000732	0.0251	CbGeAlD
Mycophenolate mofetil—CES2—lymph node—testicular cancer	0.000706	0.0242	CbGeAlD
Mycophenolate mofetil—CES1—lymph node—testicular cancer	0.000581	0.0199	CbGeAlD
Mycophenolate mofetil—ALB—testis—testicular cancer	0.000558	0.0191	CbGeAlD
Mycophenolate mofetil—ABCC2—testis—testicular cancer	0.000522	0.0179	CbGeAlD
Mycophenolate mofetil—UGT1A7—NRF2 pathway—SLC2A6—testicular cancer	0.000448	0.113	CbGpPWpGaD
Mycophenolate mofetil—ABCG2—female gonad—testicular cancer	0.00043	0.0147	CbGeAlD
Mycophenolate mofetil—CES2—NRF2 pathway—SLC2A6—testicular cancer	0.00041	0.104	CbGpPWpGaD
Mycophenolate mofetil—ALB—lymph node—testicular cancer	0.000404	0.0138	CbGeAlD
Mycophenolate mofetil—CYP3A5—female gonad—testicular cancer	0.000399	0.0137	CbGeAlD
Mycophenolate mofetil—CYP2C8—testis—testicular cancer	0.000392	0.0134	CbGeAlD
Mycophenolate mofetil—ABCB1—embryo—testicular cancer	0.000384	0.0132	CbGeAlD
Mycophenolate mofetil—ABCG2—testis—testicular cancer	0.000381	0.013	CbGeAlD
Mycophenolate mofetil—ABCC2—lymph node—testicular cancer	0.000379	0.013	CbGeAlD
Mycophenolate mofetil—ABCB1—seminal vesicle—testicular cancer	0.000361	0.0124	CbGeAlD
Mycophenolate mofetil—ABCG2—lymph node—testicular cancer	0.000276	0.00946	CbGeAlD
Mycophenolate mofetil—ABCB1—gonad—testicular cancer	0.000261	0.00893	CbGeAlD
Mycophenolate mofetil—UGT1A6—NRF2 pathway—SLC2A6—testicular cancer	0.000254	0.0643	CbGpPWpGaD
Mycophenolate mofetil—UGT1A7—Phase II conjugation—HPGDS—testicular cancer	0.000244	0.0617	CbGpPWpGaD
Mycophenolate mofetil—CES1—NRF2 pathway—SLC2A6—testicular cancer	0.000241	0.0611	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—female gonad—testicular cancer	0.000212	0.00726	CbGeAlD
Mycophenolate mofetil—UGT1A8—Phase II conjugation—HPGDS—testicular cancer	0.00019	0.048	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—testis—testicular cancer	0.000188	0.00643	CbGeAlD
Mycophenolate mofetil—UGT1A7—Biological oxidations—HPGDS—testicular cancer	0.000143	0.0361	CbGpPWpGaD
Mycophenolate mofetil—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000139	0.0351	CbGpPWpGaD
Mycophenolate mofetil—UGT1A6—Phase II conjugation—HPGDS—testicular cancer	0.000138	0.035	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—lymph node—testicular cancer	0.000136	0.00466	CbGeAlD
Mycophenolate mofetil—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.000113	0.0285	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—NRF2 pathway—SLC2A6—testicular cancer	0.000113	0.0285	CbGpPWpGaD
Mycophenolate mofetil—UGT1A8—Biological oxidations—HPGDS—testicular cancer	0.000111	0.0281	CbGpPWpGaD
Mycophenolate mofetil—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.00011	0.0278	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	9.68e-05	0.0245	CbGpPWpGaD
Mycophenolate mofetil—UGT1A6—Biological oxidations—HPGDS—testicular cancer	8.09e-05	0.0205	CbGpPWpGaD
Mycophenolate mofetil—Jaundice—Doxorubicin—testicular cancer	7.89e-05	0.0003	CcSEcCtD
Mycophenolate mofetil—Rhinitis—Epirubicin—testicular cancer	7.87e-05	0.0003	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Etoposide—testicular cancer	7.87e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Etoposide—testicular cancer	7.87e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Conjunctivitis—Doxorubicin—testicular cancer	7.87e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Urinary tract infection—Doxorubicin—testicular cancer	7.87e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Haemorrhage—Epirubicin—testicular cancer	7.85e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Hepatitis—Epirubicin—testicular cancer	7.85e-05	0.000299	CcSEcCtD
Mycophenolate mofetil—Eye disorder—Methotrexate—testicular cancer	7.84e-05	0.000298	CcSEcCtD
Mycophenolate mofetil—Tinnitus—Methotrexate—testicular cancer	7.82e-05	0.000298	CcSEcCtD
Mycophenolate mofetil—Hypoaesthesia—Epirubicin—testicular cancer	7.81e-05	0.000297	CcSEcCtD
Mycophenolate mofetil—Asthenia—Cisplatin—testicular cancer	7.8e-05	0.000297	CcSEcCtD
Mycophenolate mofetil—Pharyngitis—Epirubicin—testicular cancer	7.79e-05	0.000297	CcSEcCtD
Mycophenolate mofetil—Cardiac disorder—Methotrexate—testicular cancer	7.79e-05	0.000296	CcSEcCtD
Mycophenolate mofetil—Sweating—Doxorubicin—testicular cancer	7.76e-05	0.000295	CcSEcCtD
Mycophenolate mofetil—Urinary tract disorder—Epirubicin—testicular cancer	7.76e-05	0.000295	CcSEcCtD
Mycophenolate mofetil—Oedema peripheral—Epirubicin—testicular cancer	7.74e-05	0.000294	CcSEcCtD
Mycophenolate mofetil—Haematuria—Doxorubicin—testicular cancer	7.72e-05	0.000294	CcSEcCtD
Mycophenolate mofetil—Connective tissue disorder—Epirubicin—testicular cancer	7.72e-05	0.000294	CcSEcCtD
Mycophenolate mofetil—Urethral disorder—Epirubicin—testicular cancer	7.7e-05	0.000293	CcSEcCtD
Mycophenolate mofetil—Hepatobiliary disease—Doxorubicin—testicular cancer	7.66e-05	0.000291	CcSEcCtD
Mycophenolate mofetil—Epistaxis—Doxorubicin—testicular cancer	7.63e-05	0.000291	CcSEcCtD
Mycophenolate mofetil—Angiopathy—Methotrexate—testicular cancer	7.61e-05	0.00029	CcSEcCtD
Mycophenolate mofetil—Sinusitis—Doxorubicin—testicular cancer	7.59e-05	0.000289	CcSEcCtD
Mycophenolate mofetil—Visual impairment—Epirubicin—testicular cancer	7.57e-05	0.000288	CcSEcCtD
Mycophenolate mofetil—Mediastinal disorder—Methotrexate—testicular cancer	7.56e-05	0.000288	CcSEcCtD
Mycophenolate mofetil—Agranulocytosis—Doxorubicin—testicular cancer	7.55e-05	0.000287	CcSEcCtD
Mycophenolate mofetil—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	7.54e-05	0.0191	CbGpPWpGaD
Mycophenolate mofetil—Chills—Methotrexate—testicular cancer	7.53e-05	0.000287	CcSEcCtD
Mycophenolate mofetil—Nausea—Ifosfamide—testicular cancer	7.49e-05	0.000285	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Cisplatin—testicular cancer	7.43e-05	0.000283	CcSEcCtD
Mycophenolate mofetil—Alopecia—Methotrexate—testicular cancer	7.42e-05	0.000282	CcSEcCtD
Mycophenolate mofetil—Bradycardia—Doxorubicin—testicular cancer	7.4e-05	0.000282	CcSEcCtD
Mycophenolate mofetil—Mental disorder—Methotrexate—testicular cancer	7.35e-05	0.00028	CcSEcCtD
Mycophenolate mofetil—Eye disorder—Epirubicin—testicular cancer	7.34e-05	0.000279	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Etoposide—testicular cancer	7.33e-05	0.000279	CcSEcCtD
Mycophenolate mofetil—Tinnitus—Epirubicin—testicular cancer	7.32e-05	0.000279	CcSEcCtD
Mycophenolate mofetil—Malnutrition—Methotrexate—testicular cancer	7.31e-05	0.000278	CcSEcCtD
Mycophenolate mofetil—Haemoglobin—Doxorubicin—testicular cancer	7.3e-05	0.000278	CcSEcCtD
Mycophenolate mofetil—Cardiac disorder—Epirubicin—testicular cancer	7.29e-05	0.000277	CcSEcCtD
Mycophenolate mofetil—Rhinitis—Doxorubicin—testicular cancer	7.28e-05	0.000277	CcSEcCtD
Mycophenolate mofetil—Hepatitis—Doxorubicin—testicular cancer	7.27e-05	0.000277	CcSEcCtD
Mycophenolate mofetil—Haemorrhage—Doxorubicin—testicular cancer	7.27e-05	0.000277	CcSEcCtD
Mycophenolate mofetil—Hypoaesthesia—Doxorubicin—testicular cancer	7.23e-05	0.000275	CcSEcCtD
Mycophenolate mofetil—Pharyngitis—Doxorubicin—testicular cancer	7.21e-05	0.000274	CcSEcCtD
Mycophenolate mofetil—Urinary tract disorder—Doxorubicin—testicular cancer	7.18e-05	0.000273	CcSEcCtD
Mycophenolate mofetil—Oedema peripheral—Doxorubicin—testicular cancer	7.16e-05	0.000272	CcSEcCtD
Mycophenolate mofetil—Dysgeusia—Methotrexate—testicular cancer	7.15e-05	0.000272	CcSEcCtD
Mycophenolate mofetil—Asthenia—Etoposide—testicular cancer	7.14e-05	0.000272	CcSEcCtD
Mycophenolate mofetil—Connective tissue disorder—Doxorubicin—testicular cancer	7.14e-05	0.000272	CcSEcCtD
Mycophenolate mofetil—Angiopathy—Epirubicin—testicular cancer	7.13e-05	0.000271	CcSEcCtD
Mycophenolate mofetil—Urethral disorder—Doxorubicin—testicular cancer	7.12e-05	0.000271	CcSEcCtD
Mycophenolate mofetil—Mediastinal disorder—Epirubicin—testicular cancer	7.08e-05	0.000269	CcSEcCtD
Mycophenolate mofetil—Back pain—Methotrexate—testicular cancer	7.07e-05	0.000269	CcSEcCtD
Mycophenolate mofetil—Chills—Epirubicin—testicular cancer	7.05e-05	0.000268	CcSEcCtD
Mycophenolate mofetil—Pruritus—Etoposide—testicular cancer	7.04e-05	0.000268	CcSEcCtD
Mycophenolate mofetil—Arrhythmia—Epirubicin—testicular cancer	7.02e-05	0.000267	CcSEcCtD
Mycophenolate mofetil—Visual impairment—Doxorubicin—testicular cancer	7e-05	0.000266	CcSEcCtD
Mycophenolate mofetil—Alopecia—Epirubicin—testicular cancer	6.94e-05	0.000264	CcSEcCtD
Mycophenolate mofetil—Vomiting—Cisplatin—testicular cancer	6.91e-05	0.000263	CcSEcCtD
Mycophenolate mofetil—Mental disorder—Epirubicin—testicular cancer	6.88e-05	0.000262	CcSEcCtD
Mycophenolate mofetil—Rash—Cisplatin—testicular cancer	6.85e-05	0.000261	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Cisplatin—testicular cancer	6.84e-05	0.00026	CcSEcCtD
Mycophenolate mofetil—Malnutrition—Epirubicin—testicular cancer	6.84e-05	0.00026	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Etoposide—testicular cancer	6.81e-05	0.000259	CcSEcCtD
Mycophenolate mofetil—Eye disorder—Doxorubicin—testicular cancer	6.79e-05	0.000258	CcSEcCtD
Mycophenolate mofetil—Ill-defined disorder—Methotrexate—testicular cancer	6.78e-05	0.000258	CcSEcCtD
Mycophenolate mofetil—Tinnitus—Doxorubicin—testicular cancer	6.78e-05	0.000258	CcSEcCtD
Mycophenolate mofetil—Anaemia—Methotrexate—testicular cancer	6.75e-05	0.000257	CcSEcCtD
Mycophenolate mofetil—Cardiac disorder—Doxorubicin—testicular cancer	6.74e-05	0.000257	CcSEcCtD
Mycophenolate mofetil—Flatulence—Epirubicin—testicular cancer	6.74e-05	0.000256	CcSEcCtD
Mycophenolate mofetil—Tension—Epirubicin—testicular cancer	6.71e-05	0.000255	CcSEcCtD
Mycophenolate mofetil—Dysgeusia—Epirubicin—testicular cancer	6.69e-05	0.000255	CcSEcCtD
Mycophenolate mofetil—Nervousness—Epirubicin—testicular cancer	6.64e-05	0.000253	CcSEcCtD
Mycophenolate mofetil—Back pain—Epirubicin—testicular cancer	6.61e-05	0.000252	CcSEcCtD
Mycophenolate mofetil—Angiopathy—Doxorubicin—testicular cancer	6.59e-05	0.000251	CcSEcCtD
Mycophenolate mofetil—Malaise—Methotrexate—testicular cancer	6.59e-05	0.000251	CcSEcCtD
Mycophenolate mofetil—Dizziness—Etoposide—testicular cancer	6.58e-05	0.00025	CcSEcCtD
Mycophenolate mofetil—Muscle spasms—Epirubicin—testicular cancer	6.57e-05	0.00025	CcSEcCtD
Mycophenolate mofetil—Vertigo—Methotrexate—testicular cancer	6.56e-05	0.00025	CcSEcCtD
Mycophenolate mofetil—Mediastinal disorder—Doxorubicin—testicular cancer	6.55e-05	0.000249	CcSEcCtD
Mycophenolate mofetil—Leukopenia—Methotrexate—testicular cancer	6.54e-05	0.000249	CcSEcCtD
Mycophenolate mofetil—Chills—Doxorubicin—testicular cancer	6.52e-05	0.000248	CcSEcCtD
Mycophenolate mofetil—SLCO1B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	6.51e-05	0.0165	CbGpPWpGaD
Mycophenolate mofetil—Arrhythmia—Doxorubicin—testicular cancer	6.49e-05	0.000247	CcSEcCtD
Mycophenolate mofetil—Nausea—Cisplatin—testicular cancer	6.45e-05	0.000246	CcSEcCtD
Mycophenolate mofetil—Alopecia—Doxorubicin—testicular cancer	6.42e-05	0.000244	CcSEcCtD
Mycophenolate mofetil—Cough—Methotrexate—testicular cancer	6.37e-05	0.000243	CcSEcCtD
Mycophenolate mofetil—Mental disorder—Doxorubicin—testicular cancer	6.37e-05	0.000242	CcSEcCtD
Mycophenolate mofetil—Ill-defined disorder—Epirubicin—testicular cancer	6.34e-05	0.000241	CcSEcCtD
Mycophenolate mofetil—Convulsion—Methotrexate—testicular cancer	6.33e-05	0.000241	CcSEcCtD
Mycophenolate mofetil—Vomiting—Etoposide—testicular cancer	6.33e-05	0.000241	CcSEcCtD
Mycophenolate mofetil—Malnutrition—Doxorubicin—testicular cancer	6.33e-05	0.000241	CcSEcCtD
Mycophenolate mofetil—Anaemia—Epirubicin—testicular cancer	6.32e-05	0.00024	CcSEcCtD
Mycophenolate mofetil—Agitation—Epirubicin—testicular cancer	6.28e-05	0.000239	CcSEcCtD
Mycophenolate mofetil—Rash—Etoposide—testicular cancer	6.28e-05	0.000239	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Etoposide—testicular cancer	6.27e-05	0.000239	CcSEcCtD
Mycophenolate mofetil—Headache—Etoposide—testicular cancer	6.24e-05	0.000237	CcSEcCtD
Mycophenolate mofetil—Flatulence—Doxorubicin—testicular cancer	6.23e-05	0.000237	CcSEcCtD
Mycophenolate mofetil—Myalgia—Methotrexate—testicular cancer	6.22e-05	0.000237	CcSEcCtD
Mycophenolate mofetil—Chest pain—Methotrexate—testicular cancer	6.22e-05	0.000237	CcSEcCtD
Mycophenolate mofetil—Arthralgia—Methotrexate—testicular cancer	6.22e-05	0.000237	CcSEcCtD
Mycophenolate mofetil—Tension—Doxorubicin—testicular cancer	6.21e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Dysgeusia—Doxorubicin—testicular cancer	6.19e-05	0.000236	CcSEcCtD
Mycophenolate mofetil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	6.18e-05	0.000235	CcSEcCtD
Mycophenolate mofetil—Malaise—Epirubicin—testicular cancer	6.17e-05	0.000235	CcSEcCtD
Mycophenolate mofetil—Discomfort—Methotrexate—testicular cancer	6.14e-05	0.000234	CcSEcCtD
Mycophenolate mofetil—Nervousness—Doxorubicin—testicular cancer	6.14e-05	0.000234	CcSEcCtD
Mycophenolate mofetil—Vertigo—Epirubicin—testicular cancer	6.14e-05	0.000234	CcSEcCtD
Mycophenolate mofetil—Syncope—Epirubicin—testicular cancer	6.13e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	6.13e-05	0.0155	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—Phase II conjugation—HPGDS—testicular cancer	6.13e-05	0.0155	CbGpPWpGaD
Mycophenolate mofetil—Leukopenia—Epirubicin—testicular cancer	6.12e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Back pain—Doxorubicin—testicular cancer	6.12e-05	0.000233	CcSEcCtD
Mycophenolate mofetil—Muscle spasms—Doxorubicin—testicular cancer	6.08e-05	0.000231	CcSEcCtD
Mycophenolate mofetil—Palpitations—Epirubicin—testicular cancer	6.04e-05	0.00023	CcSEcCtD
Mycophenolate mofetil—Confusional state—Methotrexate—testicular cancer	6.01e-05	0.000229	CcSEcCtD
Mycophenolate mofetil—Loss of consciousness—Epirubicin—testicular cancer	6.01e-05	0.000229	CcSEcCtD
Mycophenolate mofetil—Cough—Epirubicin—testicular cancer	5.97e-05	0.000227	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Methotrexate—testicular cancer	5.96e-05	0.000227	CcSEcCtD
Mycophenolate mofetil—Convulsion—Epirubicin—testicular cancer	5.92e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Infection—Methotrexate—testicular cancer	5.92e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Nausea—Etoposide—testicular cancer	5.91e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Hypertension—Epirubicin—testicular cancer	5.9e-05	0.000225	CcSEcCtD
Mycophenolate mofetil—Ill-defined disorder—Doxorubicin—testicular cancer	5.87e-05	0.000223	CcSEcCtD
Mycophenolate mofetil—Nervous system disorder—Methotrexate—testicular cancer	5.85e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Anaemia—Doxorubicin—testicular cancer	5.85e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Thrombocytopenia—Methotrexate—testicular cancer	5.84e-05	0.000222	CcSEcCtD
Mycophenolate mofetil—Chest pain—Epirubicin—testicular cancer	5.82e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Myalgia—Epirubicin—testicular cancer	5.82e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Arthralgia—Epirubicin—testicular cancer	5.82e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Agitation—Doxorubicin—testicular cancer	5.81e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Anxiety—Epirubicin—testicular cancer	5.8e-05	0.000221	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Methotrexate—testicular cancer	5.79e-05	0.00022	CcSEcCtD
Mycophenolate mofetil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	5.78e-05	0.00022	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Methotrexate—testicular cancer	5.76e-05	0.000219	CcSEcCtD
Mycophenolate mofetil—Discomfort—Epirubicin—testicular cancer	5.75e-05	0.000219	CcSEcCtD
Mycophenolate mofetil—Malaise—Doxorubicin—testicular cancer	5.7e-05	0.000217	CcSEcCtD
Mycophenolate mofetil—Dry mouth—Epirubicin—testicular cancer	5.69e-05	0.000217	CcSEcCtD
Mycophenolate mofetil—Vertigo—Doxorubicin—testicular cancer	5.68e-05	0.000216	CcSEcCtD
Mycophenolate mofetil—Anorexia—Methotrexate—testicular cancer	5.68e-05	0.000216	CcSEcCtD
Mycophenolate mofetil—Syncope—Doxorubicin—testicular cancer	5.67e-05	0.000216	CcSEcCtD
Mycophenolate mofetil—Leukopenia—Doxorubicin—testicular cancer	5.66e-05	0.000215	CcSEcCtD
Mycophenolate mofetil—Confusional state—Epirubicin—testicular cancer	5.63e-05	0.000214	CcSEcCtD
Mycophenolate mofetil—Palpitations—Doxorubicin—testicular cancer	5.59e-05	0.000213	CcSEcCtD
Mycophenolate mofetil—Oedema—Epirubicin—testicular cancer	5.58e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Epirubicin—testicular cancer	5.58e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Hypotension—Methotrexate—testicular cancer	5.57e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Loss of consciousness—Doxorubicin—testicular cancer	5.56e-05	0.000212	CcSEcCtD
Mycophenolate mofetil—Infection—Epirubicin—testicular cancer	5.54e-05	0.000211	CcSEcCtD
Mycophenolate mofetil—Cough—Doxorubicin—testicular cancer	5.52e-05	0.00021	CcSEcCtD
Mycophenolate mofetil—Shock—Epirubicin—testicular cancer	5.49e-05	0.000209	CcSEcCtD
Mycophenolate mofetil—Convulsion—Doxorubicin—testicular cancer	5.48e-05	0.000209	CcSEcCtD
Mycophenolate mofetil—Nervous system disorder—Epirubicin—testicular cancer	5.47e-05	0.000208	CcSEcCtD
Mycophenolate mofetil—Thrombocytopenia—Epirubicin—testicular cancer	5.46e-05	0.000208	CcSEcCtD
Mycophenolate mofetil—Hypertension—Doxorubicin—testicular cancer	5.46e-05	0.000208	CcSEcCtD
Mycophenolate mofetil—Tachycardia—Epirubicin—testicular cancer	5.45e-05	0.000207	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Methotrexate—testicular cancer	5.43e-05	0.000207	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Epirubicin—testicular cancer	5.42e-05	0.000206	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Epirubicin—testicular cancer	5.39e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Insomnia—Methotrexate—testicular cancer	5.39e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Myalgia—Doxorubicin—testicular cancer	5.39e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Chest pain—Doxorubicin—testicular cancer	5.39e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Arthralgia—Doxorubicin—testicular cancer	5.39e-05	0.000205	CcSEcCtD
Mycophenolate mofetil—Anxiety—Doxorubicin—testicular cancer	5.37e-05	0.000204	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Methotrexate—testicular cancer	5.35e-05	0.000204	CcSEcCtD
Mycophenolate mofetil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	5.35e-05	0.000204	CcSEcCtD
Mycophenolate mofetil—Discomfort—Doxorubicin—testicular cancer	5.32e-05	0.000202	CcSEcCtD
Mycophenolate mofetil—Anorexia—Epirubicin—testicular cancer	5.32e-05	0.000202	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Methotrexate—testicular cancer	5.32e-05	0.000202	CcSEcCtD
Mycophenolate mofetil—Somnolence—Methotrexate—testicular cancer	5.3e-05	0.000202	CcSEcCtD
Mycophenolate mofetil—Dry mouth—Doxorubicin—testicular cancer	5.27e-05	0.0002	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Methotrexate—testicular cancer	5.25e-05	0.0002	CcSEcCtD
Mycophenolate mofetil—Hypotension—Epirubicin—testicular cancer	5.21e-05	0.000198	CcSEcCtD
Mycophenolate mofetil—Confusional state—Doxorubicin—testicular cancer	5.21e-05	0.000198	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Methotrexate—testicular cancer	5.18e-05	0.000197	CcSEcCtD
Mycophenolate mofetil—Oedema—Doxorubicin—testicular cancer	5.16e-05	0.000196	CcSEcCtD
Mycophenolate mofetil—Anaphylactic shock—Doxorubicin—testicular cancer	5.16e-05	0.000196	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Methotrexate—testicular cancer	5.15e-05	0.000196	CcSEcCtD
Mycophenolate mofetil—Infection—Doxorubicin—testicular cancer	5.13e-05	0.000195	CcSEcCtD
Mycophenolate mofetil—Pain—Methotrexate—testicular cancer	5.1e-05	0.000194	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.08e-05	0.000193	CcSEcCtD
Mycophenolate mofetil—Shock—Doxorubicin—testicular cancer	5.08e-05	0.000193	CcSEcCtD
Mycophenolate mofetil—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	5.07e-05	0.0128	CbGpPWpGaD
Mycophenolate mofetil—Nervous system disorder—Doxorubicin—testicular cancer	5.06e-05	0.000193	CcSEcCtD
Mycophenolate mofetil—Thrombocytopenia—Doxorubicin—testicular cancer	5.05e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Insomnia—Epirubicin—testicular cancer	5.05e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Tachycardia—Doxorubicin—testicular cancer	5.04e-05	0.000192	CcSEcCtD
Mycophenolate mofetil—Skin disorder—Doxorubicin—testicular cancer	5.01e-05	0.000191	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Epirubicin—testicular cancer	5.01e-05	0.000191	CcSEcCtD
Mycophenolate mofetil—Hyperhidrosis—Doxorubicin—testicular cancer	4.99e-05	0.00019	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Epirubicin—testicular cancer	4.97e-05	0.000189	CcSEcCtD
Mycophenolate mofetil—Somnolence—Epirubicin—testicular cancer	4.96e-05	0.000189	CcSEcCtD
Mycophenolate mofetil—Anorexia—Doxorubicin—testicular cancer	4.92e-05	0.000187	CcSEcCtD
Mycophenolate mofetil—SLCO1B3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.92e-05	0.0125	CbGpPWpGaD
Mycophenolate mofetil—Feeling abnormal—Methotrexate—testicular cancer	4.91e-05	0.000187	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Epirubicin—testicular cancer	4.91e-05	0.000187	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Methotrexate—testicular cancer	4.88e-05	0.000186	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Epirubicin—testicular cancer	4.85e-05	0.000185	CcSEcCtD
Mycophenolate mofetil—Hypotension—Doxorubicin—testicular cancer	4.82e-05	0.000184	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Epirubicin—testicular cancer	4.82e-05	0.000183	CcSEcCtD
Mycophenolate mofetil—Constipation—Epirubicin—testicular cancer	4.77e-05	0.000182	CcSEcCtD
Mycophenolate mofetil—Pain—Epirubicin—testicular cancer	4.77e-05	0.000182	CcSEcCtD
Mycophenolate mofetil—Urticaria—Methotrexate—testicular cancer	4.74e-05	0.00018	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Methotrexate—testicular cancer	4.71e-05	0.000179	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Methotrexate—testicular cancer	4.71e-05	0.000179	CcSEcCtD
Mycophenolate mofetil—Musculoskeletal discomfort—Doxorubicin—testicular cancer	4.7e-05	0.000179	CcSEcCtD
Mycophenolate mofetil—Insomnia—Doxorubicin—testicular cancer	4.67e-05	0.000178	CcSEcCtD
Mycophenolate mofetil—Paraesthesia—Doxorubicin—testicular cancer	4.64e-05	0.000176	CcSEcCtD
Mycophenolate mofetil—Dyspnoea—Doxorubicin—testicular cancer	4.6e-05	0.000175	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Epirubicin—testicular cancer	4.6e-05	0.000175	CcSEcCtD
Mycophenolate mofetil—Somnolence—Doxorubicin—testicular cancer	4.59e-05	0.000175	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Epirubicin—testicular cancer	4.56e-05	0.000174	CcSEcCtD
Mycophenolate mofetil—Dyspepsia—Doxorubicin—testicular cancer	4.54e-05	0.000173	CcSEcCtD
Mycophenolate mofetil—Decreased appetite—Doxorubicin—testicular cancer	4.49e-05	0.000171	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal disorder—Doxorubicin—testicular cancer	4.46e-05	0.00017	CcSEcCtD
Mycophenolate mofetil—Urticaria—Epirubicin—testicular cancer	4.43e-05	0.000169	CcSEcCtD
Mycophenolate mofetil—Pain—Doxorubicin—testicular cancer	4.41e-05	0.000168	CcSEcCtD
Mycophenolate mofetil—Constipation—Doxorubicin—testicular cancer	4.41e-05	0.000168	CcSEcCtD
Mycophenolate mofetil—UGT2B7—Biological oxidations—HPGDS—testicular cancer	4.41e-05	0.0112	CbGpPWpGaD
Mycophenolate mofetil—Abdominal pain—Epirubicin—testicular cancer	4.41e-05	0.000168	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Epirubicin—testicular cancer	4.41e-05	0.000168	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Methotrexate—testicular cancer	4.39e-05	0.000167	CcSEcCtD
Mycophenolate mofetil—Asthenia—Methotrexate—testicular cancer	4.28e-05	0.000163	CcSEcCtD
Mycophenolate mofetil—Feeling abnormal—Doxorubicin—testicular cancer	4.25e-05	0.000162	CcSEcCtD
Mycophenolate mofetil—Gastrointestinal pain—Doxorubicin—testicular cancer	4.22e-05	0.000161	CcSEcCtD
Mycophenolate mofetil—Pruritus—Methotrexate—testicular cancer	4.22e-05	0.000161	CcSEcCtD
Mycophenolate mofetil—Hypersensitivity—Epirubicin—testicular cancer	4.11e-05	0.000156	CcSEcCtD
Mycophenolate mofetil—Urticaria—Doxorubicin—testicular cancer	4.1e-05	0.000156	CcSEcCtD
Mycophenolate mofetil—Body temperature increased—Doxorubicin—testicular cancer	4.08e-05	0.000155	CcSEcCtD
Mycophenolate mofetil—Abdominal pain—Doxorubicin—testicular cancer	4.08e-05	0.000155	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Methotrexate—testicular cancer	4.08e-05	0.000155	CcSEcCtD
Mycophenolate mofetil—Asthenia—Epirubicin—testicular cancer	4e-05	0.000152	CcSEcCtD
Mycophenolate mofetil—Pruritus—Epirubicin—testicular cancer	3.95e-05	0.00015	CcSEcCtD
Mycophenolate mofetil—Dizziness—Methotrexate—testicular cancer	3.94e-05	0.00015	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Epirubicin—testicular cancer	3.82e-05	0.000145	CcSEcCtD
Mycophenolate mofetil—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.81e-05	0.00965	CbGpPWpGaD
Mycophenolate mofetil—Hypersensitivity—Doxorubicin—testicular cancer	3.8e-05	0.000145	CcSEcCtD
Mycophenolate mofetil—Vomiting—Methotrexate—testicular cancer	3.79e-05	0.000144	CcSEcCtD
Mycophenolate mofetil—Rash—Methotrexate—testicular cancer	3.76e-05	0.000143	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Methotrexate—testicular cancer	3.76e-05	0.000143	CcSEcCtD
Mycophenolate mofetil—Headache—Methotrexate—testicular cancer	3.73e-05	0.000142	CcSEcCtD
Mycophenolate mofetil—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	3.72e-05	0.00941	CbGpPWpGaD
Mycophenolate mofetil—Asthenia—Doxorubicin—testicular cancer	3.7e-05	0.000141	CcSEcCtD
Mycophenolate mofetil—Dizziness—Epirubicin—testicular cancer	3.69e-05	0.00014	CcSEcCtD
Mycophenolate mofetil—Pruritus—Doxorubicin—testicular cancer	3.65e-05	0.000139	CcSEcCtD
Mycophenolate mofetil—UGT1A1—Biological oxidations—HPGDS—testicular cancer	3.59e-05	0.00907	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—Biological oxidations—HPGDS—testicular cancer	3.59e-05	0.00907	CbGpPWpGaD
Mycophenolate mofetil—Vomiting—Epirubicin—testicular cancer	3.55e-05	0.000135	CcSEcCtD
Mycophenolate mofetil—Nausea—Methotrexate—testicular cancer	3.54e-05	0.000135	CcSEcCtD
Mycophenolate mofetil—Diarrhoea—Doxorubicin—testicular cancer	3.53e-05	0.000134	CcSEcCtD
Mycophenolate mofetil—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.52e-05	0.00891	CbGpPWpGaD
Mycophenolate mofetil—Rash—Epirubicin—testicular cancer	3.52e-05	0.000134	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Epirubicin—testicular cancer	3.51e-05	0.000134	CcSEcCtD
Mycophenolate mofetil—Headache—Epirubicin—testicular cancer	3.5e-05	0.000133	CcSEcCtD
Mycophenolate mofetil—Dizziness—Doxorubicin—testicular cancer	3.41e-05	0.00013	CcSEcCtD
Mycophenolate mofetil—Nausea—Epirubicin—testicular cancer	3.31e-05	0.000126	CcSEcCtD
Mycophenolate mofetil—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.31e-05	0.00837	CbGpPWpGaD
Mycophenolate mofetil—Vomiting—Doxorubicin—testicular cancer	3.28e-05	0.000125	CcSEcCtD
Mycophenolate mofetil—Rash—Doxorubicin—testicular cancer	3.26e-05	0.000124	CcSEcCtD
Mycophenolate mofetil—Dermatitis—Doxorubicin—testicular cancer	3.25e-05	0.000124	CcSEcCtD
Mycophenolate mofetil—Headache—Doxorubicin—testicular cancer	3.23e-05	0.000123	CcSEcCtD
Mycophenolate mofetil—Nausea—Doxorubicin—testicular cancer	3.07e-05	0.000117	CcSEcCtD
Mycophenolate mofetil—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.06e-05	0.00775	CbGpPWpGaD
Mycophenolate mofetil—IMPDH2—Metabolism—HPGDS—testicular cancer	2.74e-05	0.00692	CbGpPWpGaD
Mycophenolate mofetil—UGT1A7—Metabolism—HPGDS—testicular cancer	2.44e-05	0.00617	CbGpPWpGaD
Mycophenolate mofetil—IMPDH1—Metabolism—HPGDS—testicular cancer	2.23e-05	0.00564	CbGpPWpGaD
Mycophenolate mofetil—CYP3A5—Biological oxidations—HPGDS—testicular cancer	2.18e-05	0.00552	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	2.06e-05	0.00521	CbGpPWpGaD
Mycophenolate mofetil—IMPDH2—Metabolism—STK11—testicular cancer	1.99e-05	0.00503	CbGpPWpGaD
Mycophenolate mofetil—UGT1A8—Metabolism—HPGDS—testicular cancer	1.9e-05	0.0048	CbGpPWpGaD
Mycophenolate mofetil—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.89e-05	0.00478	CbGpPWpGaD
Mycophenolate mofetil—CYP2C8—Biological oxidations—HPGDS—testicular cancer	1.89e-05	0.00478	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.88e-05	0.00475	CbGpPWpGaD
Mycophenolate mofetil—UGT1A7—Metabolism—STK11—testicular cancer	1.77e-05	0.00448	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.66e-05	0.00419	CbGpPWpGaD
Mycophenolate mofetil—IMPDH1—Metabolism—STK11—testicular cancer	1.62e-05	0.0041	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.51e-05	0.00383	CbGpPWpGaD
Mycophenolate mofetil—UGT1A6—Metabolism—HPGDS—testicular cancer	1.38e-05	0.0035	CbGpPWpGaD
Mycophenolate mofetil—UGT1A8—Metabolism—STK11—testicular cancer	1.38e-05	0.00349	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.38e-05	0.00348	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.26e-05	0.00319	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.1e-05	0.00278	CbGpPWpGaD
Mycophenolate mofetil—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.01e-05	0.00256	CbGpPWpGaD
Mycophenolate mofetil—UGT1A6—Metabolism—STK11—testicular cancer	1e-05	0.00254	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B3—Metabolism—HPGDS—testicular cancer	8.37e-06	0.00212	CbGpPWpGaD
Mycophenolate mofetil—UGT2B7—Metabolism—HPGDS—testicular cancer	7.55e-06	0.00191	CbGpPWpGaD
Mycophenolate mofetil—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.25e-06	0.00183	CbGpPWpGaD
Mycophenolate mofetil—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.21e-06	0.00182	CbGpPWpGaD
Mycophenolate mofetil—UGT1A1—Metabolism—HPGDS—testicular cancer	6.13e-06	0.00155	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—Metabolism—HPGDS—testicular cancer	6.13e-06	0.00155	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B3—Metabolism—STK11—testicular cancer	6.08e-06	0.00154	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B1—Metabolism—HPGDS—testicular cancer	5.62e-06	0.00142	CbGpPWpGaD
Mycophenolate mofetil—UGT2B7—Metabolism—STK11—testicular cancer	5.48e-06	0.00139	CbGpPWpGaD
Mycophenolate mofetil—ABCG2—Metabolism—HPGDS—testicular cancer	5.2e-06	0.00132	CbGpPWpGaD
Mycophenolate mofetil—UGT1A1—Metabolism—STK11—testicular cancer	4.46e-06	0.00113	CbGpPWpGaD
Mycophenolate mofetil—UGT1A9—Metabolism—STK11—testicular cancer	4.46e-06	0.00113	CbGpPWpGaD
Mycophenolate mofetil—SLCO1B1—Metabolism—STK11—testicular cancer	4.08e-06	0.00103	CbGpPWpGaD
Mycophenolate mofetil—ABCG2—Metabolism—STK11—testicular cancer	3.78e-06	0.000957	CbGpPWpGaD
Mycophenolate mofetil—CYP3A5—Metabolism—HPGDS—testicular cancer	3.73e-06	0.000943	CbGpPWpGaD
Mycophenolate mofetil—CYP2C8—Metabolism—HPGDS—testicular cancer	3.23e-06	0.000817	CbGpPWpGaD
Mycophenolate mofetil—ALB—Metabolism—HPGDS—testicular cancer	3.21e-06	0.000813	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Metabolism—HPGDS—testicular cancer	2.81e-06	0.000712	CbGpPWpGaD
Mycophenolate mofetil—CYP3A5—Metabolism—STK11—testicular cancer	2.71e-06	0.000686	CbGpPWpGaD
Mycophenolate mofetil—CYP2C8—Metabolism—STK11—testicular cancer	2.35e-06	0.000594	CbGpPWpGaD
Mycophenolate mofetil—ALB—Metabolism—STK11—testicular cancer	2.33e-06	0.00059	CbGpPWpGaD
Mycophenolate mofetil—ABCB1—Metabolism—STK11—testicular cancer	2.04e-06	0.000517	CbGpPWpGaD
Mycophenolate mofetil—CYP3A4—Metabolism—HPGDS—testicular cancer	1.73e-06	0.000439	CbGpPWpGaD
Mycophenolate mofetil—CYP3A4—Metabolism—STK11—testicular cancer	1.26e-06	0.000319	CbGpPWpGaD
